ZIVO Bioscience, Inc. (ZIVO)
OTCMKTS · Delayed Price · Currency is USD
18.22
+0.21 (1.17%)
Aug 13, 2025, 4:01 PM EDT
ZIVO Bioscience Revenue
ZIVO Bioscience had revenue of $121.50K in the twelve months ending March 31, 2025, up 91.73% year-over-year. In the year 2024, ZIVO Bioscience had annual revenue of $157.22K with 468.61% growth.
Revenue (ttm)
121.50K
Revenue Growth
+91.73%
P/S Ratio
572.39
Revenue / Employee
17.36K
Employees
7
Market Cap
69.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 157.22K | 129.57K | 468.61% |
Dec 31, 2023 | 27.65K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 20.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 206.83M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |
ZIVO Bioscience News
- 7 weeks ago - ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry - Business Wire
- 3 months ago - University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry - Business Wire
- 6 months ago - ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry - Business Wire
- 7 months ago - ZIVO Bioscience to Present at The Microcap Conference 2025 - Business Wire
- 8 months ago - ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities - Business Wire
- 8 months ago - ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza - Business Wire
- 1 year ago - Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - GuruFocus
- 1 year ago - ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens - Business Wire